Top Ranked TSX Venture-Listed LP Eyes 32-Acre Expansion


Ryan Allway

March 8th, 2017

News, Top News


 

Canada’s cannabis industry could surpass $20 billion in size over the coming years with less than 40 licensed producers to meet the growing demand. While Canopy Growth Corp. (TSX: WEED) may be the most well-known licensed producers, there are many others that investors may want to consider for their portfolio. In particular, investors may want to seek out those that may trade at compelling valuations relative to their peers.

In this article, we will take a look at Emerald Health Therapeutics Inc.’s (TSX-V: EMH) recent developments and why investors should consider buying the stock.

TSX Venture 50 Ranked

Emerald Health is ranked third in the Clean Technology & Life Sciences sector of the 2017 TSX Venture 50 based on its market capitalization growth, share price appreciation, and trading volume. Last year, the stock price jumped nearly 500% from a low of 15 cents to over C$1.25. On February 23, the company was also featured in a video profile and official announcement of the top-ranking stocks in each sector, which could help raise investor awareness.

“Emerald is thrilled to be part of such an accomplished group of companies, and recognized for its achievements in 2016,” said Emerald Health Executive Chairman Avtar Dhillon, MD. “While last year was one of transformation for the whole industry, we expect 2017 to be a year of considerable progress for Emerald as we embark on a series of aggressive growth initiatives.”

Emerald Health is one of less than 40 licensed producers under Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR). According to Deloitte, the country’s cannabis sector could be worth more than $22.6 billion following the legalization of recreational marijuana. The lack of supplies to the large and growing market could create a shortfall over the coming years, particularly as the country begins exporting product around the world.

Ambitious Expansion Plans

Emerald Health is a demand-driven licensed producer with an expanding portfolio of proprietary genetics and upcoming clinical studies to validate safety and efficacy.

The company is well-underway with its first phase of expansion that will add 50,000 square feet of cultivation space and a state-of-the-art facility with anticipated capacity in excess of 5,000 kilograms per year. In its second phase, the company will scale-up in a modular fashion with 50,000 additional square feet in the near-term. Management anticipates that both phases will be completed in 2018 with sales commencing when licensing is completed.

The company has the capacity to build out an aggregate one million square feet of total production space on its 32-acre Metro Vancouver property.

At the same time, the company continues to expand its genetic portfolio and develop its clinical programs. The staff is in the process of characterizing unique strains with high and desirable ratios of therapeutic cannabinoids while assembling a proven cultivation team to ultimately bring them to market. The company is also collaborating with leading physicians and researchers to design clinical studies to demonstrate the efficacy of its own products.

Looking Ahead

Emerald Health Therapeutics Inc. (TSX-V: EMH) represents a compelling opportunity in Canada’s burgeoning cannabis industry. With a market capitalization of around C$100 million, the stock trades at a fraction of the value of many competing licensed producers, despite its plans to rapidly expand over the coming months. Investors may want to take a closer look at the stock for their own portfolio given these dynamics.

For more information, visit the company’s website, download its investor presentation, or visit CannabisFN’s company profile.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading